Steve Davis, Acadia Pharmaceuticals CEO
FDA advisors mostly agree that Acadia’s Nuplazid isn't effective at treating Alzheimer’s-related psychosis
A panel of the FDA’s outside experts voted 9-3 that Acadia Pharmaceuticals’ drug doesn’t appear to be effective at treating patients with Alzheimer’s-related psychosis.
The drug, Nuplazid, is already indicated for Parkinson’s-related psychosis, but Acadia has tried — and failed last year — to get another green light in dementia-related psychosis. The drug never panned out in the clinic for patients with depression, causing Acadia multiple R&D headaches over the years.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
